posted on 2015-05-08, 10:59authored byLara Christina Lewis
Pancreatic tumourigenesis is a furtive disease characterised by its lack of palpable
symptoms and the inconsistency in expression of its various diagnostic markers. The
early detection of pancreatic cancer is therefore problematic, with most patients
presenting with advanced disease resulting in limited treatment options. MicroRNAs
post-transcriptionally regulate gene expression and their aberrant expression has been
linked to disease progression in various cancers including pancreatic. In vitro studies
have shown that by manipulating microRNA expression, it is possible to inhibit
proliferation, suppress metastasis and induce drug sensitivity in pancreatic cancer cells.
The phytochemical curcumin, which is under investigation in combination treatment
trials for pancreatic cancer, is believed to alter microRNA expression.
The work presented in this thesis aimed to identify novel, aberrantly expressed
microRNAs which could potentially be used as diagnostic markers for pancreatic
cancer, and to ascertain if curcumin could modulate their expression. Additionally,
possible mechanisms by which curcumin may regulate the expression of key
microRNAs in pancreatic cancer cells when compared to non-transformed cells were
also examined.
This thesis details the identification of differentially expressed microRNAs using
microarray analysis. Cell viability and growth were assessed in order to determine a
dose and a treatment time with the capacity to elicit a biological response in pancreatic
cancer cell lines. Validation of changes observed in microRNA expression using the
microarrays was carried out using RT-qPCR. The results demonstrated that, despite
being unable to validate the differential expression of various microRNAs identified by
microarray analysis, curcumin did appear to modulate the expression of a number of
miRNAs known to be deregulated in pancreatic cancer.